Advanced Track · 5 of 5

Evidence & Regulation

Preclinical vs pilot vs RCT vs approved — and FDA vs compounded vs research-use-only

The evidence ladder

Not all "studies" are equal. Grade any claim by where it sits on this ladder:

TierWhat it means
PreclinicalCells / animals only. Hypothesis-generating, not proof in people.
Pilot / early humanSmall, often uncontrolled human studies. Signal, not proof.
RCT (Phase 2/3)Randomized, controlled, powered trials. This is real evidence.
ApprovedRegulator reviewed the full trial package.

This is exactly why every profile in our compound library shows an evidence tier — so BPC-157 ("0 Phase III") reads very differently from semaglutide ("large Phase 3 RCTs").

Three legal categories people confuse

WADA — for anyone tested

Many performance-adjacent peptides (GH secretagogues, BPC-157, TB-500, IGF-1) are prohibited by WADA — often at all times. If you're a tested athlete, "research use only" doesn't make it allowed.

How to use the News feed

Put it together: our This Week in Peptides feed tags every new paper and trial by tier and links the primary source. Read the tier first, the headline second — that habit alone puts you ahead of most of the internet.

Further reading — primary sources

  1. FDA — proposal to exclude semaglutide/tirzepatide/liraglutide from the 503B bulks list. fda.gov
  2. FDA — policies for compounders as GLP-1 supply stabilizes. fda.gov

Apply it → browse the 75-compound library

For educational and research purposes only. This content is not medical advice. Compounds referenced are research use only unless noted as approved drugs, and nothing here is an instruction to use, prepare, or administer anything. Free Peptide University does not sell compounds.